Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4520 | 298-14-6 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Approved by EMA in combination with potassium citrate.
|
| Dose | Unit | Route |
|---|---|---|
| 4 | g | O |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 30, 2021 | EMA | Advicenne S.A. | |
| None | FDA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cholelithiasis | 35.53 | 24.88 | 15 | 916 | 52491 | 90575025 |
| Acute kidney injury | 31.31 | 24.88 | 26 | 905 | 320361 | 90307155 |
| Urinary tract infection | 28.19 | 24.88 | 24 | 907 | 305608 | 90321908 |
| Disease progression | 27.22 | 24.88 | 18 | 913 | 156597 | 90470919 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Burkholderia test positive | 49.96 | 33.11 | 8 | 228 | 1042 | 42620057 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cholelithiasis | 33.74 | 26.30 | 15 | 1049 | 63407 | 110524828 |
| Disease progression | 27.52 | 26.30 | 21 | 1043 | 244013 | 110344222 |
None
| Source | Code | Description |
|---|---|---|
| ATC | A12BA04 | ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS POTASSIUM Potassium |
| CHEBI has role | CHEBI:35225 | buffer |
| CHEBI has role | CHEBI:64049 | food acidity regulator |
| CHEBI has role | CHEBI:77971 | raising agent |
| CHEBI has role | CHEBI:86328 | antifungal agrochemical |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Heartburn | indication | 16331000 | |
| Hypokalemia | indication | 43339004 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Hypokalemia Prevention | indication | ||
| Gastric Hypersecretory Conditions | indication | ||
| Hiatal Hernia with Reflux Esophagitis | indication | ||
| Multiple endocrine adenomas | off-label use | 60549007 | |
| Systemic mast cell disease | off-label use | 397016004 | DOID:349 |
| Stress-Related GI Mucosal Bleeding Prevention | off-label use | ||
| Anuria | contraindication | 2472002 | DOID:2983 |
| Hyperkalemia | contraindication | 14140009 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Chronic heart failure | contraindication | 48447003 | |
| Congenital myotonia, autosomal dominant form | contraindication | 57938005 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hyperchloremia | contraindication | 74450001 | |
| Third degree burn injury | contraindication | 80247002 | |
| Oliguria | contraindication | 83128009 | |
| Hyporeninemic hypoaldosteronism | contraindication | 236464008 | |
| Edema | contraindication | 267038008 | |
| Familial hyperkalemic periodic paralysis | contraindication | 304737009 | DOID:14451 |
| Azotemia | contraindication | 445009001 | |
| Severe dehydration | contraindication | 450316000 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| D02077 | KEGG_DRUG |
| 4017518 | VUID |
| N0000145903 | NUI |
| 4017518 | VANDF |
| CHEBI:81862 | CHEBI |
| CHEMBL2106975 | ChEMBL_ID |
| C026329 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB11098 | DRUGBANK_ID |
| 34296 | RXNORM |
| 1810 | MMSL |
| 5324 | MMSL |
| d03600 | MMSL |
| 000745 | NDDF |
| 000765 | NDDF |
| 419980002 | SNOMEDCT_US |
| 77849004 | SNOMEDCT_US |
| C0071751 | UMLSCUI |
| 516893 | PUBCHEM_CID |
| HM5Z15LEBN | UNII |
| HM5Z15LEBN | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| KLOR-Con/EF | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-5326 | TABLET, EFFERVESCENT | 978 mg | ORAL | unapproved drug other | 20 sections |
| Alka-Seltzer Gold | HUMAN OTC DRUG LABEL | 3 | 0280-4100 | TABLET, EFFERVESCENT | 344 mg | ORAL | OTC Monograph Drug | 16 sections |
| TowerX Effervescent Potassium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50201-2400 | TABLET, EFFERVESCENT | 25 meq | ORAL | unapproved drug other | 17 sections |
| Effer-K Orange | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-001 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
| Effer-K Lemon Citrus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-005 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
| Effer-K Cherry Berry | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-006 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
| Effer-K Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-007 | TABLET, EFFERVESCENT | 977.50 mg | ORAL | UNAPPROVED DRUG OTHER | 21 sections |
| Effer-K 20 mEq Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-011 | TABLET, EFFERVESCENT | 782 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Effer-K 20 mEq Orange Cream | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-012 | TABLET, EFFERVESCENT | 782 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Effer-K 10 mEq Unflavored | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-013 | TABLET, EFFERVESCENT | 391 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Effer-K 10 mEq Cherry Vanilla | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51801-014 | TABLET, EFFERVESCENT | 391 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Pleo Alkala Antacid | HUMAN OTC DRUG LABEL | 3 | 60681-6001 | POWDER | 117 g | ORAL | OTC monograph final | 13 sections |
| Relief OTC antacid | HUMAN OTC DRUG LABEL | 3 | 69016-001 | LIQUID | 905 mg | ORAL | OTC monograph final | 14 sections |